The Next Biomanufacturing Revolution: Stable Cell Lines for CAR-T

Biomanufacturing complexity, yield and cost have long constrained the promise of cell and gene therapies. In this webinar, featured speakers will explore the transformative potential of stable producer cell lines and how they’re poised to reshape CAR-T and viral vector production. These technologies once enabled monoclonal antibodies to evolve from niche laboratory tools into a $200 billion global market.

Webinar attendees will learn how many lessons from over 30 years of Chinese hamster ovary (CHO)-based antibody manufacturing can be applied to today’s CAR-T scale-out challenges. The speakers will also discuss why conventional transient transfection processes often struggle to keep pace with the escalating demand for next-generation therapies. They will unpack the quantitative advantages of stable versus transient methods through practical comparisons and illustrate how a novel platform addresses critical hurdles such as toxicity, low titers and regulatory consistency. Attendees will learn about the downstream benefits for cost reduction, timeline acceleration and broader patient access.

By reviewing data that demonstrate how core hurdles in stable cell line development have been overcome, attendees will gain valuable insights into overcoming common challenges. The webinar will also unveil a novel cell pool strategy designed to slash upfront time and investment, offering a data-driven roadmap for integrating stable cell line strategies into CMC workflows.

Whether a scientist optimizing bioprocesses, a CMC professional overseeing clinical manufacturing or a business leader charting commercialization strategy, this session will equip attendees with the insights needed to break the biomanufacturing bottleneck.

Register for this webinar to discover how stable cell lines can cut production costs, boost therapeutic yields and unlock truly scalable, GMP-compliant CAR-T biomanufacturing.

Speakers

Johanna Goldmann, Business Development Manager, ProBioGen

Johanna Goldmann is a Business Development Manager for viral vectors and cell and gene therapy at ProBioGen. Trained at the Scripps Research Institute, the Massachusetts Institute of Technology (MIT) and the Centre for Genome Regulation, she brings together cutting-edge science and commercial strategy. Johanna has authored numerous publications in leading journals and helped establish strategic partnerships to advance vector scale-up and support the adoption of next-generation therapies. Her expertise in translating complex research into scalable, GMP-compliant solutions strengthens ProBioGens position in CAR-T and viral vector manufacturing. Johanna’s commitment to innovation continues to contribute to the field of cell and gene therapy commercialization.

Message Presenter

Sophia Sörensen, Research Scientist, ProBioGen

Sophia Sörensen is a Research Scientist with over 12 years of experience at ProBioGen, currently working in the Viral Vectors and Gene Therapeutics department. She holds an MSc in Biotechnology from the Berlin University of Applied Sciences. Sophia began her career in cell line development for protein-based biologics, focusing on the generation of high-producing cell lines for CHO-based antibody production. She later transitioned to viral vectors, playing a key role in developing stable lentiviral packaging and producer cell lines. Her contributions were instrumental in establishing Lenti.RiGHT^®, ProBioGen’s scalable lentiviral vector platform. Today, she and her team drive innovations in vector yield and scalability — across both lentiviral and AAV systems — through strategic cell line optimization and advanced process development.

Message Presenter